Instem plc Director/PDMR Shareholding (5293V)
January 15 2013 - 2:00AM
UK Regulatory
TIDMINS
RNS Number : 5293V
Instem plc
15 January 2013
15 January 2013
Instem plc
("Instem", or the "Company")
Director/PDMR Shareholding
Instem plc (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, announces that Chief
Executive Officer, Phil Reason has been granted options over 23,429
ordinary shares of 10p each ("Ordinary Shares") and Chief Financial
Officer, Nigel Goldsmith has been granted options over 15,000
Ordinary Shares. These options become exercisable after a period of
three years subject to market based performance criteria, pursuant
to the rules of the Company's All Staff LTIP and approved by the
Remuneration Committee on 18 December 2012. The exercise price of
90p represents the closing mid-market price of the Ordinary Shares
as at 14 January 2013.
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser &
Broker) +44 (0) 20 7496 3000
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT solutions to the early
development healthcare market. Instem's pre-clinical study
management solutions accelerate drug and chemical development by
increasing productivity, automating processes and enhancing
practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China,
India and Japan, including 16 of the top 20 pharmaceutical and
biotech companies such as GlaxoSmithKline and AstraZeneca. The
Group employs over 110 people in seven offices in the US, UK, China
and India; and has a full service distributor in Japan. It is
estimated that approximately half of the world's pre-clinical drug
safety data has been collected over the last 20 years via Instem
software, making Instem an ideal partner to help unlock the
scientific/commercial value from these legacy repositories.
To learn more about Instem please visit the Company's website,
www.instem.com, or its investor centre
http://investors.instem.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBRGDBRSBBGXS
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024